1. Home
  2. ADXN vs BIVI Comparison

ADXN vs BIVI Comparison

Compare ADXN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

N/A

Current Price

$8.44

Market Cap

9.6M

Sector

Health Care

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.37

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADXN
BIVI
Founded
2002
2013
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
10.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADXN
BIVI
Price
$8.44
$1.37
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
54.1K
Earning Date
12-04-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$198,824.00
N/A
Revenue This Year
$86.57
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.51
$1.25
52 Week High
$12.05
$25.76

Technical Indicators

Market Signals
Indicator
ADXN
BIVI
Relative Strength Index (RSI) 52.16 37.14
Support Level $7.47 $1.40
Resistance Level $8.30 $1.51
Average True Range (ATR) 0.45 0.10
MACD 0.06 -0.00
Stochastic Oscillator 72.22 2.94

Price Performance

Historical Comparison
ADXN
BIVI

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: